enGene Holdings Inc reports results for the quarter ended April 30 - Earnings Summary

• enGene Holdings Inc ENGN.OQ reported a quarterly adjusted loss of 51 cents​​ per share for the quarter ended April 30, lower than the same quarter last year, when the company reported EPS of -38 cents. The mean expectation of ten analysts for the quarter was for a loss of 50 cents per share. Wall Street expected results to range from -60 cents to -32 cents per share.

• Reported revenue was zero​; analysts expected zero.

• enGene Holdings Inc's reported EPS for the quarter was a loss of 51 cents​.

• The company reported a quarterly loss of $25.82 million.

• enGene Holdings Inc shares had fallen by 28.1% this quarter and lost 51.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for enGene Holdings Inc is $25.00

This summary was machine generated from LSEG data June 12 at 12:33 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)